A Busy Calendar of March Biotech Events

March is a catalyst-rich month for biotech and drug stocks. 

Two FDA drug approval decisions this month. On March 19, Endo Health's (ENDP) Impavido to treat leishmaniasis, and on March 21, Celgene's (CELG) Otezla for psoriatic arthritis.

In Europe, Endocyte (ECYT) and Merck (MRK) are expecting a decision on accelerated approval for their ovarian cancer therapy vintafolide following the CHMP meeting scheduled for March 17-20. The announcement decision will come no later than March 21.

Three significant FDA advisory committee meetings to look forward to later this month.

On March 26-27 the FDA's Molecular and Clinical Genetics Panel will review two non-invasive screening tests for colon cancer: Epigenomics' blood-based Epi proColon and Exact Sciences' (EXAS) stool-based Cologuard. Look for FDA briefing documents for Epigenomics on March 24 and Exact Sciences on March 25.

On March 31, the FDA's Anti-Infective Drugs Advisory Committee will review two new antibiotics: Cubist Pharmaceuticals' CBST tedizolid and Durata Therapeutics' (DRTX) dalbavancin. FDA briefing documents will be posted to the agency's web site on March 27.

On April 1, the Endocrinologic and Metabolic Drugs Advisory Committee will review MannKind's (MNKD) inhaled, rapid-acting insulin Afrezza. The Afrezza FDA panel counts as a March event because FDA briefing documents will be made available on March 28.

On the clinical side:

Top-line results from a phase II study of Insmed's (INSM) Arikace in lung disease caused by nontuberculous mycobacteria (NTM).

Top-line results from a phase II study of Endocyte and Merck's vintafolide in non-small lung cancer.

Prana Biotech (PRAN) will announce results from a phase II study of PBT2 in Alzheimer's disease.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

More from Investing

The Best Investment Advice? Stay Diversified

The Best Investment Advice? Stay Diversified

Attention 60 Minutes: Google Isn't the Only Big-Tech Monopoly

Attention 60 Minutes: Google Isn't the Only Big-Tech Monopoly

After PayPal Buys iZettle, Pay-Tech Firms Could Process These Deals

After PayPal Buys iZettle, Pay-Tech Firms Could Process These Deals

Listen: Should You Buy Cisco Now?

Listen: Should You Buy Cisco Now?

Amazon Could Devastate Walgreens and Rite Aid by Getting Into Pharmacy Business

Amazon Could Devastate Walgreens and Rite Aid by Getting Into Pharmacy Business